

# Derek Gilroy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8844894/publications.pdf>

Version: 2024-02-01

142  
papers

21,465  
citations

30551

56  
h-index

22488

117  
g-index

145  
all docs

145  
docs citations

145  
times ranked

32996  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 680-690.	1.1	8
2	Clinical, Cellular, and Molecular Effects of Corticosteroids on the Response to Intradermal Lipopolysaccharide Administration in Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 964-971.	2.3	3
3	Dying cell-derived SAM switches off inflammation. <i>Nature Metabolism</i> , 2022, , .	5.1	0
4	Treating exuberant, non-resolving inflammation in the lung; Implications for acute respiratory distress syndrome and COVID-19. , 2021, 221, 107745.		8
5	Beyond dexamethasone, emerging immunothrombotic therapies for COVID-19. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 845-857.	1.1	6
6	Recruitment of inflammatory monocytes by senescent fibroblasts inhibits antigen-specific tissue immunity during human aging. <i>Nature Aging</i> , 2021, 1, 101-113.	5.3	39
7	A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis. <i>New England Journal of Medicine</i> , 2021, 384, 808-817.	13.9	181
8	Asymmetric Synthesis and Biological Screening of Quinoxaline-Containing Synthetic Lipoxin A <sub>4</sub> Mimetics (QNX-sLXms). <i>Journal of Medicinal Chemistry</i> , 2021, 64, 9193-9216.	2.9	18
9	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway. <i>JHEP Reports</i> , 2021, 3, 100332.	2.6	6
10	Resolving inflammation. <i>Nature Reviews Immunology</i> , 2021, 21, 620-621.	10.6	3
11	Potent anti-inflammatory effects of an H <sub>2</sub> S-releasing naproxen (ATB-346) in a human model of inflammation. <i>FASEB Journal</i> , 2021, 35, e21913.	0.2	4
12	Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study. <i>Lancet Microbe</i> , The, 2021, 2, e508-e517.	3.4	52
13	Ageing immunity may exacerbate COVID-19. <i>Science</i> , 2020, 369, 256-257.	6.0	166
14	Sestrins induce natural killer function in senescent-like CD8+ T cells. <i>Nature Immunology</i> , 2020, 21, 684-694.	7.0	139
15	Blocking elevated p38 MAPK restores efferocytosis and inflammatory resolution in the elderly. <i>Nature Immunology</i> , 2020, 21, 615-625.	7.0	87
16	FRI-112-Prediction of treatment failures in a multicentre feasibility trial using human albumin solution to prevent infection in acute decompensation of liver cirrhosis. <i>Journal of Hepatology</i> , 2019, 70, e436.	1.8	0
17	FRI-109-Increased plasma leukotriene B4 in decompensated cirrhosis associates with disease progression and leads to increased skin window neutrophil infiltration. <i>Journal of Hepatology</i> , 2019, 70, e435.	1.8	1
18	Lipid mediators in immune regulation and resolution. <i>British Journal of Pharmacology</i> , 2019, 176, 1009-1023.	2.7	74

#	ARTICLE	IF	CITATIONS
19	Is Resolution the End of Inflammation?. Trends in Molecular Medicine, 2019, 25, 198-214.	3.5	131
20	Chronic inflammation in the etiology of disease across the life span. Nature Medicine, 2019, 25, 1822-1832.	15.2	2,195
21	Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 738-747.e7.	2.4	47
22	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. Clinical Gastroenterology and Hepatology, 2018, 16, 748-755.e6.	2.4	19
23	Potent Anti-Inflammatory and Pro-Resolving Effects of Anabasum in a Human Model of Self-Resolving Acute Inflammation. Clinical Pharmacology and Therapeutics, 2018, 104, 675-686.	2.3	52
24	ATTIRE: Albumin To prevent Infection in chronic liver failure: study protocol for an interventional randomised controlled trial. BMJ Open, 2018, 8, e023754.	0.8	22
25	Pro-resolving mediators promote resolution in a human skin model of UV-killed Escherichia coli-driven acute inflammation. JCI Insight, 2018, 3, .	2.3	66
26	OWE-015...Prostaglandin E2 mediates innate immune suppression in acute-on-chronic liver failure via the EP4 receptor. , 2018, , .		0
27	A sestrin-dependent Erk/Jnk/p38 MAPK activation complex inhibits immunity during aging. Nature Immunology, 2017, 18, 354-363.	7.0	223
28	Pre/pro-B cells generate macrophage populations during homeostasis and inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E3954-E3963.	3.3	32
29	The fate and lifespan of human monocyte subsets in steady state and systemic inflammation. Journal of Experimental Medicine, 2017, 214, 1913-1923.	4.2	725
30	Inflammatory Resolution Triggers a Prolonged Phase of Immune Suppression through COX-1/mPGES-1-Derived Prostaglandin E 2. Cell Reports, 2017, 20, 3162-3175.	2.9	69
31	Albumin binding capacity is impaired in decompensated liver cirrhosis and dysfunction is reversed by targeted in vivo 20% human albumin solution infusions. Journal of Hepatology, 2017, 66, S390.	1.8	0
32	Plasma lipid mediator (LM) profiling identifies hyper- and hypo-activated groups of patients with ACLF and targeted 20% human albumin solution infusion recalibrates abnormalities. Journal of Hepatology, 2017, 66, S390.	1.8	0
33	Exaggerated Onset and Delayed Resolution of Acute Inflammation in Ulcerative Colitis. Gastroenterology, 2017, 152, S996.	0.6	0
34	5-Aminosalicylates Promote Generation of Anti-Inflammatory Hydroxy Fatty Acids that Contribute to Inflammation Resolution in Ulcerative Colitis. Gastroenterology, 2017, 152, S996-S997.	0.6	0
35	Infarct size in a rat model of acute myocardial infarction is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-il-6r monoclonal antibody. Heart, 2017, 103, A146.2-A146.	1.2	0
36	Lipid Mediators in Inflammation. , 2017, , 343-366.		3

#	ARTICLE	IF	CITATIONS
37	Prolonged immune alteration following resolution of acute inflammation in humans. <i>PLoS ONE</i> , 2017, 12, e0186964.	1.1	23
38	P4940 Infarct size in a rat model of STEMI is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-IL6R monoclonal antibody. <i>European Heart Journal</i> , 2017, 38, .	1.0	0
39	A Comparison of Human Neutrophils Acquired from Four Experimental Models of Inflammation. <i>PLoS ONE</i> , 2016, 11, e0165502.	1.1	7
40	CYP450-derived oxylipins mediate inflammatory resolution. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E3240-9.	3.3	107
41	Novel translational model of resolving inflammation triggered by UV-killed <i>E. coli</i> . <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 154-165.	1.3	24
42	Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences. <i>Liver International</i> , 2016, 36, 837-846.	1.9	20
43	Lipid Mediators in Inflammation. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	115
44	Intravenous Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate Systemic Inflammation. <i>Journal of Visualized Experiments</i> , 2016, , .	0.2	28
45	Resolution of inflammation: a new therapeutic frontier. <i>Nature Reviews Drug Discovery</i> , 2016, 15, 551-567.	21.5	642
46	ATTIRE: Albumin To prevent Infection in chronic liver failure: study protocol for a single-arm feasibility trial. <i>BMJ Open</i> , 2016, 6, e010132.	0.8	7
47	P1327 : Attire: albumin to prevent infection in chronic liver failure. <i>Journal of Hepatology</i> , 2015, 62, S853.	1.8	0
48	Sex-specific regulation of chemokine Cxcl5/6 controls neutrophil recruitment and tissue injury in acute inflammatory states. <i>Biology of Sex Differences</i> , 2015, 6, 27.	1.8	29
49	New insights into the resolution of inflammation. <i>Seminars in Immunology</i> , 2015, 27, 161-168.	2.7	115
50	Intimal smooth muscle cells are a source but not a sensor of anti-inflammatory CYP450 derived oxylipins. <i>Biochemical and Biophysical Research Communications</i> , 2015, 463, 774-780.	1.0	10
51	Macrophage development and polarization in chronic inflammation. <i>Seminars in Immunology</i> , 2015, 27, 257-266.	2.7	97
52	HIF1 $\alpha$ Allows Monocytes to Take a Breather during Sepsis. <i>Immunity</i> , 2015, 42, 397-399.	6.6	6
53	Characterisation of Leukocytes in a Human Skin Blister Model of Acute Inflammation and Resolution. <i>PLoS ONE</i> , 2014, 9, e89375.	1.1	27
54	Resolution of acute inflammation bridges the gap between innate and adaptive immunity. <i>Blood</i> , 2014, 124, 1748-1764.	0.6	142

#	ARTICLE	IF	CITATIONS
55	Inflammatory triggers of acute rejection of organ allografts. <i>Immunological Reviews</i> , 2014, 258, 132-144.	2.8	105
56	O154 PROSTAGLANDIN E2 MEDIATES IMMUNOSUPPRESSION IN ACUTELY DECOMPENSATED CIRRHOSIS. <i>Journal of Hepatology</i> , 2014, 60, S64.	1.8	0
57	Lipid mediators in immune dysfunction after severe inflammation. <i>Trends in Immunology</i> , 2014, 35, 12-21.	2.9	78
58	Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation. <i>Immunity</i> , 2014, 40, 315-327.	6.6	666
59	Secretory leukocyte protease inhibitor: A pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. <i>Hepatology</i> , 2014, 59, 1564-1576.	3.6	80
60	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. <i>Immunity</i> , 2014, 41, 339-340.	6.6	53
61	Macrophage Activation and Polarization: Nomenclature and Experimental Guidelines. <i>Immunity</i> , 2014, 41, 14-20.	6.6	4,638
62	Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. <i>Nature Medicine</i> , 2014, 20, 518-523.	15.2	240
63	The resolution of inflammation. <i>Nature Reviews Immunology</i> , 2013, 13, 59-66.	10.6	454
64	57 SECRETORY LEUKOCYTE PROTEASE INHIBITOR (SLPI) IS A PIVOTAL MEDIATOR OF ANTI-INFLAMMATORY RESPONSES IN ACUTE LIVER FAILURE. <i>Journal of Hepatology</i> , 2013, 58, S26.	1.8	0
65	Pathways mediating resolution of inflammation: when enough is too much. <i>Journal of Pathology</i> , 2013, 231, 8-20.	2.1	61
66	SP0135â€¦Mononuclear cells and the reoslution of acute inflammation. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 33.4-34.	0.5	0
67	The Effect of Pro-Inflammatory Conditioning and/or High Glucose on Telomere Shortening of Aging Fibroblasts. <i>PLoS ONE</i> , 2013, 8, e73756.	1.1	16
68	Inducible CYP2J2 and Its Product 11,12-EET Promotes Bacterial Phagocytosis: A Role for CYP2J2 Deficiency in the Pathogenesis of Crohnâ€™s Disease?. <i>PLoS ONE</i> , 2013, 8, e75107.	1.1	37
69	Assessment of Leukocyte Trafficking in Humans using the Cantharidin Blister Model. <i>JRSM Cardiovascular Disease</i> , 2012, 1, 1-5.	0.4	7
70	Old and new generation lipid mediators in acute inflammation and resolution. <i>Progress in Lipid Research</i> , 2011, 50, 35-51.	5.3	271
71	Transcriptomic analyses of murine resolution-phase macrophages. <i>Blood</i> , 2011, 118, e192-e208.	0.6	253
72	Inhibition of the diclofenacâ€-induced cyclooxygenaseâ€2 activity by paracetamol in cultured macrophages is not related to the intracellular lipid hydroperoxide tone. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 186-190.	1.0	3

#	ARTICLE	IF	CITATIONS
73	Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice. <i>Blood</i> , 2011, 118, 5918-5927.	0.6	236
74	Endogenous Epoxygenases Are Modulators of Monocyte/Macrophage Activity. <i>PLoS ONE</i> , 2011, 6, e26591.	1.1	71
75	Resolution of Acute Inflammation and Wound Healing. , 2010, , 17-27.		2
76	Lipid Mediators in Acute Inflammation and Resolution: Eicosanoids, PAF, Resolvins, and Protectins. , 2010, , 153-174.		10
77	Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. <i>Blood</i> , 2010, 116, 2950-2959.	0.6	52
78	A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis. <i>FEBS Letters</i> , 2010, 584, 3955-3961.	1.3	40
79	Dichotomy in duration and severity of acute inflammatory responses in humans arising from differentially expressed proresolution pathways. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 8842-8847.	3.3	106
80	Eicosanoids and the endogenous control of acute inflammatory resolution. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 524-528.	1.2	39
81	Directed issue: Novel concepts in inflammation. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 480-481.	1.2	2
82	A New Strategy for the Identification of Novel Molecules with Targeted Proresolution of Inflammation Properties. <i>Journal of Immunology</i> , 2010, 184, 1516-1525.	0.4	96
83	In Vivo Models to Study Cyclooxygenase Products in Health and Disease: Introduction to Part III. <i>Methods in Molecular Biology</i> , 2010, 644, 181-188.	0.4	7
84	Nonresolving Inflammation in gp91phox <sup>-/-</sup> Mice, a Model of Human Chronic Granulomatous Disease, Has Lower Adenosine and Cyclic Adenosine 5'-Monophosphate. <i>Journal of Immunology</i> , 2009, 182, 3262-3269.	0.4	25
85	Effects of Low-Dose Aspirin on Acute Inflammatory Responses in Humans. <i>Journal of Immunology</i> , 2009, 183, 2089-2096.	0.4	272
86	Regulation of growth and survival of activated T cells by cell-transducing inhibitors of Ras. <i>FEBS Letters</i> , 2009, 583, 61-69.	1.3	4
87	Low-dose acetylsalicylic acid inhibits the secretion of interleukin-6 from white adipose tissue. <i>International Journal of Obesity</i> , 2008, 32, 1807-1815.	1.6	18
88	The resolution of acute inflammation: A "tipping point" in the development of chronic inflammatory diseases. , 2008, , 1-18.		10
89	Novel biphasic role for lymphocytes revealed during resolving inflammation. <i>Blood</i> , 2008, 111, 4184-4192.	0.6	65
90	Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. <i>Blood</i> , 2008, 112, 4117-4127.	0.6	280

#	ARTICLE	IF	CITATIONS
91	Hematopoietic prostaglandin D <sub>2</sub> synthase controls the onset and resolution of acute inflammation through PGD <sub>2</sub> and 15-deoxy- $\Delta^{14}$ -PGJ <sub>2</sub> . Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20979-20984.	3.3	230
92	Elucidation of the temporal relationship between endothelial-derived NO and EDHF in mesenteric vessels. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 293, H1682-H1688.	1.5	21
93	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2007, 21, 325-332.	0.2	949
94	Not all eicosanoids are bad. Trends in Pharmacological Sciences, 2006, 27, 609-611.	4.0	8
95	New Perspectives on Aspirin and the Endogenous Control of Acute Inflammatory Resolution. Scientific World Journal, The, 2006, 6, 1048-1065.	0.8	25
96	Resolution of inflammation: state of the art, definitions and terms. FASEB Journal, 2006, , 672271.	0.2	4
97	Chronic inflammation: a failure of resolution?. International Journal of Experimental Pathology, 2006, 88, 85-94.	0.6	275
98	Targeting Lipoxygenases with Care. Chemistry and Biology, 2006, 13, 1121-1122.	6.2	4
99	Essential role for hematopoietic prostaglandin D <sub>2</sub> synthase in the control of delayed type hypersensitivity. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 5179-5184.	3.3	122
100	COX-2 in Inflammation and Resolution. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 199-207.	3.4	141
101	Prostaglandin F <sub>2</sub> $\alpha$ produced by inducible cyclooxygenase may contribute to the resolution of inflammation. Inflammopharmacology, 2005, 12, 473-476.	1.9	16
102	New insights into the anti-inflammatory actions of aspirin- induction of nitric oxide through the generation of epi-lipoxins. Memorias Do Instituto Oswaldo Cruz, 2005, 100, 49-54.	0.8	39
103	Resolution for Sepsis?. Circulation, 2005, 111, 2-4.	1.6	10
104	Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Current Opinion in Pharmacology, 2005, 5, 405-411.	1.7	42
105	The role of aspirin-triggered lipoxins in the mechanism of action of aspirin. Prostaglandins Leukotrienes and Essential Fatty Acids, 2005, 73, 203-210.	1.0	36
106	A novel role for phospholipase A <sub>2</sub> isoforms in the checkpoint control of acute inflammation. FASEB Journal, 2004, 18, 489-498.	0.2	174
107	15-epi-lipoxin A <sub>4</sub> -mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation. Journal of Experimental Medicine, 2004, 200, 69-78.	4.2	215
108	Inflammatory Resolution: new opportunities for drug discovery. Nature Reviews Drug Discovery, 2004, 3, 401-416.	21.5	664

#	ARTICLE	IF	CITATIONS
109	Reduced infiltration and increased apoptosis of leukocytes at sites of inflammation by systemic administration of a membrane-permeable I $\beta$ B? repressor. <i>Arthritis and Rheumatism</i> , 2004, 50, 2675-2684.	6.7	41
110	The endogenous control of acute inflammation " from onset to resolution. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 313-319.	0.5	9
111	Inducible cyclooxygenase-derived 15deoxy $\Gamma$ 12 $\epsilon$ 14 PGJ 2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. <i>FASEB Journal</i> , 2003, 17, 2269-2271.	0.2	135
112	Attenuation of glucocorticoid functions in an Anx-A1-/- cell line. <i>Biochemical Journal</i> , 2003, 371, 927-935.	1.7	57
113	Inhibition of NF- $\kappa$ B Activity by a Membrane-Transducing Mutant of I $\beta$ B $\pm$ . <i>Journal of Immunology</i> , 2002, 169, 2587-2593.	0.4	50
114	Purification and characterization of a cyclooxygenase $\epsilon$ 2 and angiogenesis suppressing factor produced by human fibroblasts. <i>FASEB Journal</i> , 2002, 16, 1286-1288.	0.2	23
115	Anti-inflammatory lipid mediators and insights into the resolution of inflammation. <i>Nature Reviews Immunology</i> , 2002, 2, 787-795.	10.6	751
116	Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells. <i>British Journal of Pharmacology</i> , 2002, 135, 511-519.	2.7	131
117	Cell cycle-dependent expression of cyclooxygenase $\epsilon$ 2 in human fibroblasts. <i>FASEB Journal</i> , 2001, 15, 288-290.	0.2	36
118	Potential Adverse Effects of Cyclooxygenase-2 Inhibition. <i>BioDrugs</i> , 2001, 15, 1-9.	2.2	26
119	Selective Suppression of CCAAT/Enhancer-binding Protein $\Gamma$ 2 Binding and Cyclooxygenase-2 Promoter Activity by Sodium Salicylate in Quiescent Human Fibroblasts. <i>Journal of Biological Chemistry</i> , 2001, 276, 18897-18904.	1.6	82
120	COX-2 expression and cell cycle progression in human fibroblasts. <i>American Journal of Physiology - Cell Physiology</i> , 2001, 281, C188-C194.	2.1	28
121	New insights into inflammatory resolution. <i>Inflammopharmacology</i> , 2001, 9, 125-130.	1.9	1
122	Possible new role for NF- $\kappa$ B in the resolution of inflammation. <i>Nature Medicine</i> , 2001, 7, 1291-1297.	15.2	971
123	Colocalization and Interaction of Cyclooxygenase-2 with Caveolin-1 in Human Fibroblasts. <i>Journal of Biological Chemistry</i> , 2001, 276, 34975-34982.	1.6	82
124	Nitric Oxide Synthase Inhibitors Have Opposite Effects on Acute Inflammation Depending on Their Route of Administration. <i>Journal of Immunology</i> , 2001, 166, 1169-1177.	0.4	68
125	Resolution of inflammation. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1131-1135.	1.1	121
126	COX-2 and the cyclopentenone prostaglandins - a new chapter in the book of inflammation?. <i>Prostaglandins and Other Lipid Mediators</i> , 2000, 62, 33-43.	1.0	45



#	ARTICLE	IF	CITATIONS
127	New insights into the role of COX 2 in inflammation. <i>Journal of Molecular Medicine</i> , 2000, 78, 121-129.	1.7	113
128	Cyclooxygenase enzymes as targets for therapeutic intervention in inflammation. <i>Drug News and Perspectives</i> , 2000, 13, 587.	1.9	11
129	Effects of hyaluronan on models of immediate and delayed hypersensitivity in the rat. <i>International Journal of Immunopharmacology</i> , 1999, 21, 195-203.	1.1	3
130	Inducible cyclooxygenase may have anti-inflammatory properties. <i>Nature Medicine</i> , 1999, 5, 698-701.	15.2	1,168
131	The role of the inducible enzymes cyclooxygenase-2, nitric oxide synthase and heme oxygenase in angiogenesis of inflammation. , 1999, , 125-147.		1
132	The effects of cyclooxygenase 2 inhibitors on cartilage erosion and bone loss in a model of <i>Mycobacterium tuberculosis</i> -induced monoarticular arthritis in the rat. <i>Inflammation</i> , 1998, 22, 509-519.	1.7	35
133	Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. <i>European Journal of Pharmacology</i> , 1998, 355, 211-217.	1.7	116
134	Differential effects of inhibition of isoforms of cyclooxygenase (COX-1, COX-2) in chronic inflammation. <i>Inflammation Research</i> , 1998, 47, 79-85.	1.6	92
135	Inducible enzymes with special reference to COX-2 in inflammation and apoptosis. , 1996, , 67-83.		11
136	Cyclooxygenase and nitric oxide synthase isoforms in rat carrageenin-induced pleurisy. <i>British Journal of Pharmacology</i> , 1994, 113, 693-698.	2.7	199
137	Neutrophil-Endothelial Cell Interactions. , 0, , 141-152.		1
138	Nonsteroidal Anti-Inflammatory Drugs. , 0, , 234-243.		0
139	Gastrointestinal Inflammation and Ulceration: Mediators of Induction and Resolution. , 0, , 282-298.		0
140	Inflammation in Cardiovascular Diseases. , 0, , 317-328.		0
141	Macrophages. , 0, , 96-106.		0
142	Lung. , 0, , 253-258.		0